Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review-MedSci.cn

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review

Chen, S; Marcella, E; Susanto, B; Tandiono, J; Heriyanto, RS; Wijovi, F; Tancherla, A; Kurniawan, A

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (4): S779

科室
- - 订阅+
  - 更多科室
工具
服务